Compare · AZN vs FBRX
AZN vs FBRX
Side-by-side comparison of AstraZeneca PLC (AZN) and Forte Biosciences Inc. (FBRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and FBRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 261.8x FBRX ($1.00B).
- Over the past year, AZN is down 10.3% and FBRX is up 361.5% - FBRX leads by 371.8 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 6 for FBRX).
- AZN has more recent analyst coverage (25 ratings vs 12 for FBRX).
- Company
- AstraZeneca PLC
- Forte Biosciences Inc.
- Price
- $168.85-0.24%
- $48.92+8.45%
- Market cap
- $261.92B
- $1.00B
- 1M return
- -5.56%
- +185.08%
- 1Y return
- -10.32%
- +361.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2017
- News (4w)
- 15
- 6
- Recent ratings
- 25
- 12
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Forte Biosciences Inc.
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest FBRX
- Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.
- Forte Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
- Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.
- CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.57% to 42,600 units (SEC Form 4)
- Officer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 85,482 units (SEC Form 4)
- SEC Form 4 filed by CHIEF FINANCIAL OFFICER Riley Antony A
- SEC Form 4 filed by Officer Wagner Paul A.
- SEC Form EFFECT filed by Forte Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Forte Biosciences Inc.